Introduction
============

Neuropathic pain (NP) is a severe and intolerable disease and is considered one of the most difficult pain syndromes to treat due to its complex pathogenesis ([@B10]). Despite decades of study, the currently available drugs largely fail to control NP.

Koumine, an indole alkaloid isolated from *Gelsemium elegans*, has shown diverse pharmacological actions including antitumor, anti-inflammatory, anxiolytic, and analgesic activity ([@B16]; [@B34]; [@B5]). We recently reported the analgesic effect of koumine in various animal pain models, such as chronic constriction injury (CCI), spared nerve injury, diabetic NP, and rheumatoid arthritis pain models ([@B32]; [@B21]; [@B28]; [@B33]; [@B31]; [@B15]). Koumine displayed high efficiency and low toxicity in the treatment of NP, implying that this compound may have potential as a new anti-NP drug. However, its analgesic mechanism against NP still needs to be further explored.

The mechanisms of NP are involved in both peripheral and central sensitization, but the precise mechanism is still unclear ([@B23]). In recent years, spinal astrocytes have been reported to play a significant role in the induction and maintenance of NP ([@B24]). Astrocytes, which form close contacts with neuronal synapses, constitute the most abundant cell type in the central nervous system. Under some circumstances, such as peripheral nerve injury, tissue damage, and arthritis, spinal astrocytes rapidly transform to an activated state, which displays a closer correlation with chronic pain behaviors ([@B9]). Activated astrocytes can regulate the release of neurotrophic factors, inflammatory mediators, chemokines, adenosine and neurotransmitters, resulting in long-lasting thermal hyperalgesia and mechanical allodynia ([@B35]). Although the pathogenesis of NP has not yet been fully elucidated, an inflammatory response caused by astrocyte activation is considered one of the most critical events. Therefore, decreasing spinal astrocyte activation by using pharmacotherapeutic approaches could be a therapeutic strategy for NP ([@B9]; [@B30]).

Autophagy is a process in which cells use lysosomes to degrade their own damaged organelles and macromolecules, which is an important mechanism for cell survival, differentiation, and development ([@B26]). Under physiological conditions, autophagy is maintained at a low level. Under endoplasmic reticulum stress, however, autophagy is activated as a defense mechanism, playing an important role in maintaining intracellular environmental homeostasis. In recent years, a number of studies have shown that impairment of autophagy plays an important part in the occurrence and development of NP ([@B18]). In contrast, upregulation of autophagy can slow the process of NP ([@B20]; [@B22]; [@B3]; [@B14]). Interestingly, relatively few studies have revealed any participation of autophagy in astrocyte functions that are related to CNS diseases such as Alzheimer's disease, cerebral ischemia, and spinal cord injury ([@B12]; [@B11]; [@B27]). According to a recent report, Schwann cells, the neuroglia found in the peripheral nervous system, are involved in the development and maintenance of NP through regulation of autophagy ([@B22]). All these findings prompted us to explore the analgesic effect of koumine and its molecular mechanism involved in astrocyte autophagy. The mitochondria-mediated pathway is one of the most important signaling pathways in apoptosis, and energy depletion in mitochondria is an early event in CCI rats ([@B19]). Furthermore, to clarify the protective effects via the mitochondria-mediated apoptosis pathway, were examined the expression levels of related proteins.

We previously described that the attenuation of NP by koumine may result from the inhibition of neuroglial activation and inflammation response. Here, we extended the initial study and investigated the underlying analgesic mechanisms of koumine, focusing on astrocyte activation, autophagy and apoptosis in the spinal cord.

Materials and Methods {#s1}
=====================

Animals
-------

Male Sprague-Dawley rats, weighing 150--180 g or born within 24 h of each other, were provided by the Department of Experimental Animal Center, Fujian Medical University. The rats were housed 6--7 per cage and were provided *ad libitum* access to laboratory chow and water. The rodents were maintained at a constant room temperature (25 ± 2°C), with a regular 12:12-h light/dark schedule, with lights on from 08:00 to 20:00. The rats were used for experiments after an acclimation period of 3--7 days. The experimental protocols were approved by the ethics committee at Fujian Medical University (No: 2016-026), and the study was conducted in accordance with the guidelines published in the NIH Guide for the Care and Use of Laboratory Animals.

Drugs
-----

Koumine (PubChem CID: 91895267; purity \>98.5%, HPLC; **Figure [1A](#F1){ref-type="fig"}**) was isolated from *Gelsemium elegans* Benth. via pH-zone-refining countercurrent chromatography, which has been described in our previous study ([@B29]). Koumine was subcutaneously (s.c.) administered at a dose volume of 4 ml/kg dissolved in sterile physiological saline (0.9% NaCl). Chloroquine (CQ), purchased from Sigma (St. Louis, MO, United States), was intrathecally administered at 0.1 μg (20 μL) 15 min after koumine administration.

![Koumine (KM) displayed an antinociceptive effect. **(A)** Structural formula of koumine. **(B)** Effects of koumine on mechanical allodynia in rats with CCI neuropathy. Rats were conducted Sham or CCI operation. The day of operation was regarded as day 0. Koumine (0.28, 7 mg/kg) or vehicle was administered subcutaneously (s.c.) once per day for seven consecutive days from postoperative day 3. The mechanical withdrawal threshold was measured before surgery (baseline) and drug treatment (predosing), and 1 h after drug administration (postdosing). Data indicate withdrawal threshold for the ipsilateral paw as the mean ± SEM. ^\#\#\#^*P* \< 0.001 versus Sham group. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, and ^∗∗∗^*P* \< 0.001 versus vehicle control group, two-way repeated-measures ANOVA followed by LSD or Dunnett's T3 test for each time point.](fphar-09-00989-g001){#F1}

CCI Model Preparation
---------------------

The CCI model was established as previously described ([@B2]). Briefly, the rats were anesthetized with pentobarbital sodium (40 mg/kg, i.p.), and blunt dissection was performed on the biceps brachii to expose the sciatic nerve. Following separation, the sciatic nerve was ligated with 4.0 silk at 1 mm intervals. A sham group underwent the same surgery, but without ligation. Afterward, the muscle and skin incisions were closed separately.

Behavioral Testing
------------------

The mechanical withdrawal threshold (MWT) was assessed using an electronic von Frey device (series 2390; IITC Life Science Inc., Woodland Hills, CA, United States), as previously described ([@B25]; [@B15]). All tests were performed by a behavioral investigator blinded to the pharmacological treatment of the animals.

Primary Astrocyte Cultures and Cell Viability Assay
---------------------------------------------------

The primary astrocyte cultures and cell viability assay were as previously described ([@B17]).

Western Blot
------------

Rats were anesthetized with sodium pentobarbital after behavioral testing. The L4--L5 spinal segments were quickly isolated and collected in a tissue lysis buffer containing protease inhibitors. Insoluble pellets were separated by centrifugation (14000 × *g* for 30 min, 4°C). The protein samples were quantified by a BCA protein assay kit. The protein samples from the astrocytes were handled as previously described ([@B15]). The blot was incubated overnight at 4°C with the primary antibodies mouse polyclonal anti-GAPDH (1:3000, TransGen Biotech, Beijing, China), mouse polyclonal anti-GFAP, rabbit polyclonal anti-LC3B (1:1000, Cell Signaling Technology, Beverly, MA, United States), rabbit polyclonal anti-Beclin 1, rabbit polyclonal anti-p62 (1:1000, MBL International Corporation, Nagoya, Japan), anti-Bcl-xl, anti-Bax, and anti-cleaved caspase-3 (1:1000, Beyotime, Shanghai, China), followed by goat anti-mouse horseradish peroxidase-labeled antibody (1:5000, Jackson Immuno Research Labs Inc., West Grove, PA, United States) or goat anti-rabbit horseradish peroxidase-labeled antibody (1:5000, Jackson Immuno Research Labs Inc., West Grove, PA, United States) for 1 h at room temperature. After these processes, membranes were washed thrice with TBST. Chemiluminescence was detected by using Carestream Molecular Imaging system for 1--5 min. Equal protein loading was confirmed in all the experiments by using GAPDH as loading control. The intensity of each selected band was analyzed using NIH Image J software.

Immunofluorescence
------------------

The lumbar spinal cord segments were removed and postfixed in the fixative overnight. Tissue was then maintained in 30% sucrose in 0.1 M PBS at 4°C overnight. Dissected tissue was mounted in OCT compound and frozen at -20°C. The transverse spinal cord was cut at a thickness of 25 μm in a cryostat (Microm HM 505E). For immunohistochemistry analysis, the sections were washed in 0.01 M PBS 3 times (5 min each) and then blocked with 10% normal goat serum in 0.3% Triton X-100 for 1 h. After being blocked, the sections were incubated overnight at 4°C in the dark with a primary antibody, either anti-GFAP polyclonal antibody or LC3 polyclonal antibody (1:200; Cell Signaling Technology, Beverly, MA, United States). The sections were then washed three times with PBS for 10 min each and incubated with Alexa Fluor 488 anti-mouse antibody (1:200, Jackson Immuno Research Labs Inc., West Grove, PA, United States) and Alexa Fluor 594 anti-rabbit antibody (1:400, Jackson Immuno Research Labs Inc., West Grove, PA, United States) in blocking solution without Triton X-100 for 45 min in the dark. Negative staining controls were prepared by omitting either the primary antibody or secondary antibody. Fluorescent images of these sections were captured with a digital camera (Nikon 80i, Japan), and the fluorescence density was analyzed using a computer software (Image-Pro Plus 6, Media Cybernetics, United States).

Electron Microscope
-------------------

Rat spinal cords selected at random from each group were fixed in 4% neutral buffered paraformaldehyde, and then dehydrated for 24 h. After that, spinal cords were embedded in paraffin wax, cut into 3 μm-thick slices, and then examined via electron microscope (Hitachi Co. Ltd., Tokyo, Japan) operated at 75 kV.

ELISA
-----

After behavioral testing was complete, rat spinal cords were collected, homogenized, and then stored at -80°C. Total TNF-α, IL-6, and IL-1β levels were measured using ELISA Kits (Abcam, ab46070 for TNF-α and ab100768 for IL-1β, Cambridge, MA, United States) according to the manufacturer's instructions.

TUNEL Staining
--------------

After the rats were sacrificed, the tissues were embedded, sectioned, and deparaffinized. The sections were performed using TUNEL kits according to the manufacturer's instructions (Beyotime, C1088, Shanghai, China). Sections were observed under a light microscope (Olympus, Tokyo, Japan).

Statistical Analysis
--------------------

Data are expressed as the mean ± SEM. Two-way repeated-measures analysis of variance (ANOVA) was used for behavior test. For analysis of immunohistochemistry, ELISA and Western blot analysis, the data were analyzed by one-way ANOVA followed by Dunnett's *post hoc* test or the least significant difference (LSD) test, respectively. *P*-value \<0.05 was defined significant.

Results
=======

Koumine Displayed Antinociceptive Effect and Promoted Autophagy in CCI Rats
---------------------------------------------------------------------------

Similar to previous studies ([@B15]), the present study displayed that repeated subcutaneous administration of KM significantly alleviates NP in CCI rats (**Figure [1B](#F1){ref-type="fig"}**). To further assess the hypothesis that koumine promotes autophagy in CCI-induced NP rats, we evaluated LC3, Beclin-1, and p62 levels in the rat spinal cord by Western blot. As shown in **Figure [2A](#F2){ref-type="fig"}**, the level of Beclin-1 showed no remarkable changes among the sham, vehicle-treated CCI and koumine-treated CCI groups. However, a significant increase in the ratio of LC3-II to LC3-I protein was observed after CCI operation in comparison to the sham group (*P* \< 0.01). The koumine-treated CCI group further decreased its LC3-II/I ratio compared to vehicle-treated CCI group (*P \<* 0.05, **Figure [2B](#F2){ref-type="fig"}**). SQSTM1/p62 is a critical autophagy protein, and the expression of SQSTM1/p62 may increase when autophagy is impaired. Consistent with the previously study, the protein level of CCI group displayed a significant increase compared to the sham group (*P \<* 0.01, **Figure [2C](#F2){ref-type="fig"}**), and koumine treatment reversed this effect (*P \<* 0.05). In addition, transmission electron micrograph showed the characteristics of the autophagosome structure in spinal cord of rats. Double layer or multilayer membrane and inclusions which contains cytoplasm components such as mitochondria, endoplasmic reticulum were displayed by red arrow (**Figure [2D](#F2){ref-type="fig"}**). Transmission electron micrograph analysis showed an increase in autophagosome formation in the koumine treatment group compared to the CCI group. These results indicate that koumine attenuates NP and alleviates the impaired autophagy in the spinal cord of rats.

![Koumine promoted autophagy in CCI rats. Beclin 1 **(A)**, LC3 **(B)**, and p62 **(C)** levels were detected by Western blot in the spinal cord. **(D)** Spinal cord sections were analyzed by light microscopy electron microscope (scale bar = 500 nm), double layer or multilayer membrane and inclusions are the characteristics of the autophagosome structure which contains mitochondria, endoplasmic reticulum, ribosome, and other cytoplasm components (red arrow). ^\#\#^*P* \< 0.05 versus sham group. ^∗^*P* \< 0.05 versus vehicle control group by one-way ANOVA followed by LSD test.](fphar-09-00989-g002){#F2}

Koumine-Induced Autophagy Occurred in Astrocytes in CCI Rats
------------------------------------------------------------

We previously reported that koumine significantly decreased astrocyte activation as reflected by the specific marker GFAP in spinal cord sections ([@B15]). To further investigate whether koumine-induced autophagy occurred in astrocytes, we co-immunostained the spinal cord sections with LC3 and GFAP (**Figure [3A](#F3){ref-type="fig"}**). In the spinal dorsal horn of the operated side, the LC3 staining showed a high level of colocalization with GFAP-positive glial cells in saline-treated CCI group (*P \<* 0.001), while koumine treatment greatly decreased the positive cells of GFAP and LC3, as well as colocalization of LC3 and GFAP (*P \<* 0.001, **Figure [3B](#F3){ref-type="fig"}**). These results indicated that koumine's alleviation of the impaired autophagy may occur in astrocytes in the spinal cord of CCI rats.

![Koumine (KM) inhibit GFAP protein levels in rat spinal cord with CCI neuropathy. **(A)** After CCI or Sham surgery, koumine (0.28, 7 mg/kg) or vehicle was administered s.c. once a day, every day for seven consecutive days from postoperative TSPO and LC3 was determined by Immunofluorescence. **(B)** The number of LC3/GFAP positive cells. The scale bar represents 25 μm. Data are expressed as the mean ± SEM. ^\#\#\#^*P* \< 0.001 versus Sham group. ^∗∗∗^*P* \< 0.001 versus vehicle control group, separate one-way ANOVA followed by LSD test.](fphar-09-00989-g003){#F3}

Koumine Enhances Astrocyte Autophagy and Attenuates Astrocyte Activation, As Well As the Inflammation Response in Lipopolysaccharide (LPS)-Exposed Primary Astrocytes
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

To further confirm that koumine directly inhibited astrocyte reactivation and inflammation response, we performed Western blotting and ELISA testing in LPS-exposed rat primary astrocytes. First, we determined that several concentrations of koumine (0, 25, 50, and 100 μM) had no effect on cell viability at several concentrations after treatment for 24, 36, or 48 h by MTT assay (data not shown). Consequently, we pretreated the astrocytes with koumine (or vehicle) for 12 h and then stimulated them with LPS for 24 h to induce reactivation. In agreement with our previous reports, koumine, significantly reduced GFAP expression and the levels of IL-1β and TNF-α (**Figures [4A,B,F,G](#F4){ref-type="fig"}**). These results are consistent with our *in vivo* findings. In addition, we explored the effects of koumine on LPS-induced autophagy in primary astrocytes. We found the levels of Beclin-1 protein in astrocytes treated with LPS was not affected, the expression of p62 and the ratio of LC3-II/LC3-I increased significantly (*P \<* 0.05), indicated LPS induces activation of astrocytes while activating autophagy. However, the increased expression of LC3-II/LC3-I and p62 protein induced by LPS could be inhibited by koumine (**Figures [4A,C,D,E](#F4){ref-type="fig"}**).

![Koumine (KM) enhances LPS-induced astrocyte autophagy and attenuates astrocyte activation, as well as inflammation response in LPS-exposed primary astrocytes. Cultured astrocytes were exposed to koumine (0, 25, 50, or 100 μM) for 12 h prior to exposure to LPS for an additional 24 h before testing. Astrocytes in the control group were incubated with standard culture medium lacking koumine and LPS. Western blot **(A)** and densitometric quantification of GFAP **(B)**, Beclin 1 **(C)**, LC3-I/LC3-II **(D)**, P62 **(E)**, and GAPDH were performed in LPS-exposed astrocytes. Elisa were performed to explore the LPS-induced production of TNF-α **(F)** and IL-1β **(G)** in cultured astrocytes. Data are presented as the mean ± SEM. of three independent experiments. ^\#\#\#^*P* \< 0.001, ^\#\#^*P* \< 0.01, and ^\#^*P* \< 0.05 compared with the control group. ^∗∗∗^*P* \< 0.001, ^∗∗^*P* \< 0.01, and ^∗^*P* \< 0.05 compared with the LPS group, as determined by one-way ANOVA followed by the LSD test.](fphar-09-00989-g004){#F4}

Blockage of Autophagy Activity Diminished Analgesia Effect of Koumine
---------------------------------------------------------------------

To assess the pro-autophagic activity of koumine in the development of mechanical allodynia in CCI rats, we injected koumine subcutaneously for two consecutive days beginning on day 3 after the CCI operation, then autophagy inhibitor chloroquine (CQ) was administered. As shown in **Figure [5A](#F5){ref-type="fig"}**, in the CCI+KM group, repeat subcutaneous injection of koumine (7 mg/kg) significantly increased MWT (*P \<* 0.05 for postoperative day 4, *P \<* 0.01 for postoperative day 5). In the CCI+KM+CQ group, we selected the dose of CQ (0.1 μg, intrathecal injection) which did not affect the MWT. Interestingly, the increases in MWT caused by koumine were abolished by CQ (*P \<* 0.1 for postoperative day 5). These data indicate that the analgesic effect of koumine was abolished by the autophagy inhibitor chloroquine.

![Blockage of autophagy activity diminished effect of koumine (KM) on MWT and astrocyte activation in CCI rats. **(A)** The antagonistic effect of chloroquine (CQ) against antinociceptive effect of koumine. Data indicate the withdrawal threshold for the ipsilateral paw as the mean ± SEM (*n* = 5--7 per group). ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01 compared with the CCI+NS group. ^\#\#^*P* \< 0.01 compared with the versus CCI+KM+NS group, two-way repeated-measures ANOVA followed by LSD or Dunnett's T3 test for each time point. **(B)** GFAP level was detected by Western blot in the spinal cord. **(C)** Pro-inflammatory cytokine IL-1β and TNF-α in spinal cord of CCI rats after the koumine (KM) and CQ administered. Data are expressed as the mean ± SEM. ^\#\#^*P* \< 0.01 versus CCI+NS group. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, and ^∗∗∗^*P* \< 0.001 versus CCI+KM group, separate one-way ANOVA followed by LSD test.](fphar-09-00989-g005){#F5}

Blockage of Autophagy Activity Diminished the Effect of Koumine on Astrocyte Activation in CCI Rats
---------------------------------------------------------------------------------------------------

We sought to further investigate whether the analgesic effect of koumine was linked to the inhibition of astrocyte activation via the promotion of autophagy in the spinal cord of CCI rats. We next detected GFAP and pro-inflammatory cytokine in the spinal cord of CCI rats after koumine and CQ were administered. As shown in **Figure [5B](#F5){ref-type="fig"}**, Western blot results showed that the levels of GFAP decreased after koumine treatment (*P* \< 0.01, compared with the CCI+NS group), whereas the effect of koumine on inhibition of astrocyte activation was abolished by CQ (*P* \< 0.05, compared to KM group). Although a slight increase in GFAP protein level in CQ alone group was recorded, it was non-significant (*P* \> 0.05, compared to CCI+NS group). Similar observations were made for IL-1β and TNF-α, the pro-inflammatory cytokine closely related to pain. The ELISA results showed KM that significantly decreased IL-1β and TNF-α protein expression (*P* \< 0.01, compared to CCI+NS group), but reversed by CQ (*P* \< 0.01 for TNF-α, *P* \< 0.001 for IL-1β, compared to CCI+KM group), no significant differences were observed in CQ and NS groups (**Figure [5C](#F5){ref-type="fig"}**). In addition, although the level of Beclin-1 has no remarkable changes compared to vehicle-treated CCI and CQ-treated CCI groups, it presented a decreasing trend (*P* \< 0.05, **Figure [6](#F6){ref-type="fig"}**). LC3-II/I and p62 expression were decreased compared to vehicle-treated CCI group and CQ-treated CCI groups, suggesting that blockage of autophagy activity diminished the effect of koumine on astrocyte activation in CCI rats.

![Koumine (KM) promoted autophagy in CCI rats. Beclin 1 **(A)**, LC3 **(B)**, and p62 **(C)** levels were detected by Western blot in the spinal cord. ^\#\#^*P \<* 0.05 versus Sham group. ^∗^*P \<* 0.05 and ^∗∗^*P \<* 0.01 versus vehicle control group by one-way ANOVA followed by LSD test.](fphar-09-00989-g006){#F6}

Effects of Koumine on Apoptosis-Related Protein in CCI Rats
-----------------------------------------------------------

Apoptosis was reported to be associated with the development of NP. We further investigated whether apoptosis was involved in the analgesic effects of koumine on CCI-induced NP. TUNEL staining of the rat spinal cord indicated that TUNEL-positive nuclei (co-immunostained TUNEL staining with DAPI) were present throughout the spinal cord, and their numbers were decreased by koumine (**Figure [7A](#F7){ref-type="fig"}**). Quantification of the apoptosis incidence (TUNEL- and DAPI-positive cells/DAPI-positive cells, **Figure [7B](#F7){ref-type="fig"}**) revealed a high occurrence (41%), which koumine treatment could decrease to 11% (*P* \< 0.001, compared to CCI+NS group). Interestingly, this effect was abolished by CQ (*P \<* 0.001, compared to CCI+KM group). Then, we costained GFAP with TUNEL in the spinal cord of CCI rats, the TUNEL staining almost invisible colocalization with GFAP positive glia cells (**Figure [7C](#F7){ref-type="fig"}**). Moreover, apoptosis related proteins were quantified by Western blot. The protein expression levels of cleaved caspase-3 and pro-apoptotic Bax protein were downregulated while anti-apoptotic Bcl-xl protein was upregulated after treatment with koumine (**Figures [7D,E](#F7){ref-type="fig"}**). Furthermore, CQ significantly decreased Bcl-xl and increased Bax and cleaved caspase-3 protein levels.

![The effect of koumine (KM) on apoptosis in spinal cord tissue of CCI rats. **(A)** Apoptotic cells in rat spinal cord tissue through TUNEL staining. **(B)** Quantification of apoptotic cells in spinal cord tissue. **(C)** Representative immunofluorescence staining for glial fibrillary acidic protein (Red) and TUNEL-positive cells (green) merged double staining. Western Blot experiment **(D)** and the relative quantification **(E)** for apoptosis related protein Bcl-xl, cleaved caspase-3, and Bax protein expression in CCI rats with drug treatment. All results were obtained from three independent experiments. ^\#\#^*P \<* 0.01 and ^\#\#\#^*P \<* 0.001 versus CCI+NS group. ^∗^*P \<* 0.05, ^∗∗^*P* \< 0.01, and ^∗∗∗^*P* \< 0.001 versus CCI+KM group by one-way ANOVA followed by LSD test.](fphar-09-00989-g007){#F7}

Discussion
==========

This research illustrated that analgesic effect of koumine, which might be modulated in part by attenuating astrocyte activation and the levels of pro-inflammatory cytokines via inducing autophagic flux and suppressing apoptosis in rats with CCI-induced NP.

The pathophysiological mechanism of NP is complex. However, an increasing amount of evidence suggests that neuroinflammation---characterized by activation of glia (including microglia and astrocytes) and pro-inflammatory cytokines---is an important factor in the development and maintenance of central sensitization and NP. Both activated microglia and astrocytes are participants in the NP and could be the main sources pro-inflammatory cytokines. Notably, microglia were activated at the early phase of the disease, whereas activated astrocytes were detected in the sustainment phase. The activation of astrocytes can release pro-inflammatory cytokines (such as TNF-α and IL-1β) and chemotactic factor, which, in turn, activate glia and neurons, eventually forming a positive feedback loop of glia-to-neuron signals, creating perseverative release of pain mediators. Astrocyte activation has been found in various injury conditions such as CCI, spinal nerve ligation (SNL), tissue injury, and inflammation, which are associated with enhanced pain states. Fluorocitrate, an astrocyte activation inhibitor, was able to relieve the mechanical pain in NP. Therefore, inhibition of astrocyte activation can be one of the new strategies to treat NP. In the present study, we investigate the astrocyte activation in CCI-induced NP rats. We found a significant activation of astrocytes, as shown by the increase in GFAP, which was decreased by treatment of koumine. In addition, TNF-α and IL-1β, the key pro-inflammatory pain mediators, were upregulated in the spinal dorsal horn following CCI and that koumine treatment markedly inhibited its productions. As activated astrocytes can be a source of TNF-α and IL-1β, these results imply that the analgesic effect of koumine may involve inhibiting astrocyte activation and pro-inflammatory cytokine production.

In recent years, the effect of autophagy in NP has attracted the attention of researchers. The impairment of autophagy occurred in NP was first described in the SNL mice and further confirmed in other experimental models of NP ([@B4], [@B3]). In turn, enhancing autophagy by pharmacological approaches has been reported to be a potential manner for slowing the onset and chronification of NP ([@B22]; [@B11]). To investigate the correlation between autophagy and analgesic effect of koumine on NP, we assessed the changes in expression of LC3, Beclin1 and p62 in the spinal cord of CCI rats following treatment with koumine. After CCI operation, the rat displayed significant mechanical allodynia; meanwhile, the ratio of LC3-II/I and the expression of p62 increased significantly in the spinal cord, while Beclin-1 did not, suggesting that autophagic flux was blocked in the late stage of autophagy. In turn, administration of koumine significantly reversed mechanical allodynia, paralleled by decrease in LC3-II/I and p62, indicating that autophagy was enhanced by koumine. This evidence suggest the analgesic effect of koumine may be involved in enhancing autophagy in the spinal cord of NP rats. Indeed, several autophagy mediators were demonstrated to be effective in CNS diseases including NP. For example, simvastatin can contribute to neuroprotection after spinal cord injury by inducing autophagy ([@B8]). Rapamycin, an autophagy inducer, significantly attenuates NP by enhancing autophagy and inhibiting IL-1β expression in the microglia of the spinal cord ([@B7]). Ginsenoside compound K was reported to enhance autophagy in primary astrocytes by target of mTOR (mammalian target of rapamycin), which may promote β-amyloid peptide clearance and slow the pathological progression of AD ([@B12]). In contrast, blocking autophagy by pharmacological approaches can induce or enhance NP ([@B3]). We found intrathecal injection CQ significantly diminishing the analgesic effect of koumine, which could also explain the analgesic activity of koumine on NP may be involved in promoting autophagy in rat spinal cord.

Although the precise mechanism of autophagy's contribution to NP is not well understood, changes in autophagy flux in glial cells may play an important role. As koumine displayed strong inhibitory activity against astrocyte activation and promoting autophagy on spinal cord of rat. We further explored whether koumine could inhibit astrocyte activation by promoting astrocyte autophagy. Our studies demonstrated that LC3 staining showed a large number of colocalization with GFAP positive glia cells, suggesting that autophagy may occur in astrocytes of the spinal cord. Koumine treatment decreases the number of LC3/GFAP positive cells, indicating that koumine inhibits astrocyte activation and promotes astrocyte autophagy. On treatment with the autophagy inhibitor CQ, the inhibition effect of koumine on astrocyte activation was attenuated, along with the key pro-inflammatory molecules TNF-α and IL-1β. In cultured rat primary astrocytes, we found that koumine significantly decreased the upregulation of LC3II/LC3I and p62 protein induced by LPS, indicated koumine can promote the degradation of autophagic bodies and maintain the smooth flow of autophagy in astrocytes. Taken together, these results suggest that koumine may inhibit astrocyte activation by enhancing autophagy.

Autophagy is closely associated with apoptosis in many diseases, including NP, neurodegenerative diseases, and cancer. As a form of programmed cell death, apoptosis was reported to be associated with the development of NP ([@B1]; [@B36]). Caspases and Bcl-2 family proteins, including the pro-apoptosis protein Bax and the pro-survival protein Bcl-xl, play a pivotal role in cell survival and death ([@B6]). Interestingly, koumine was reported to serve as a protective effect against LPS-induced apoptosis on RAW 264.7 cells. In the present study, we demonstrated that the CCI model induced caspase-dependent apoptosis by significantly increasing Bax and cleaved caspase-3 and decreasing Bcl-xl expression. Koumine shown inhibit apoptosis and protective properties and may be a therapeutic agent for treating NP in CCI rats. However, we costained for GFAP and TUNEL in the rat spinal cord and revealed that unusual apoptosis occurred in astrocytes. It was reported that positive costaining of TUNEL and Nissl body cells indicates that a majority of apoptotic cells are neurons in NP animals. In addition, TNF-α and IL-1β, which are well known to take part in the regulation of cellular apoptosis ([@B13]). As we have demonstrated koumine significantly reduced the TNF-α and IL-1β expression in the spinal cord, we deduced that the main source of these apoptosis cells are neurons, while this needs to be further investigated.

Conclusion
==========

The present study showed that autophagy was impaired in CCI-induced NP rats. Koumine treatment significantly enhanced autophagy and inhibited apoptosis and astrocyte activation as well as IL-1β and TNF-α production in the spinal cord, and the treatment also ameliorated CCI-induced mechanical allodynia (**Figure [8](#F8){ref-type="fig"}**). In the long term, koumine may provide useful innovative therapeutic strategies for the treatment of NP in clinical practice.

![Proposed mechanisms of the effect of koumine in CCI rats. Koumine attenuates neuropathic pain through promoting astrocyte autophagy, inhibiting astrocyte excessive activation, decreasing astrocyte-mediated neuroinflammation and apoptosis.](fphar-09-00989-g008){#F8}

Author Contributions
====================

G-lJ and R-cY performed the experiments, analyzed the data, prepared the figures, and drafted the manuscript. S-dH and L-mH contributed to the experiments. YX analyzed the data and prepared the figures. C-xY conceived and designed the study. All authors have read and approved the final manuscript.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This work was supported by the National Natural Science Foundation of China (Grant Nos. 81603094 and 81773716), the Joint Funds for the Innovation of Science and Technology, Fujian province (Grant Nos. 2016Y9049 and 2016Y9058), the Natural Science Foundation of Fujian Province of China (Grant No. 2016J05191), and the special support funds for the science and technology innovation leader, Fujian province (Grant No. 2016B017).

We would like to thank Jeffrey Ong for language assistance.

[^1]: Edited by: Francisco R. Nieto, University of Granada, Spain

[^2]: Reviewed by: Michael Morgan, The University of Queensland, Australia; Zhouguang Wang, Wenzhou Medical University, China; Rafael Gonzalez-Cano, Harvard University, United States

[^3]: ^†^These authors have contributed equally to this work

[^4]: This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology
